mammarenaviru
lassa
lasv
highli
preval
west
africa
infect
sever
hundr
thousand
individu
annual
result
high
number
lassa
fever
lf
case
febril
diseas
associ
high
morbid
signific
mortal
mount
evid
indic
worldwidedistribut
prototyp
mammarenaviru
lymphocyt
choriomening
viru
lcmv
neglect
human
pathogen
clinic
signific
food
drug
administr
fda
licens
vaccin
current
antimammarenaviru
therapi
limit
offlabel
use
ribavirin
partial
effect
caus
signific
side
effect
therefor
unmet
need
novel
antivir
drug
combat
lasv
task
would
facilit
implement
high
throughput
screen
ht
identifi
inhibitor
activ
viru
ribonucleoprotein
vrnp
respons
direct
viru
rna
genom
replic
gene
transcript
use
live
lasv
purpos
jeopard
requir
biosafeti
level
contain
develop
virusfre
cell
platform
express
level
report
gene
serv
accur
surrog
vrnp
activ
develop
cellbas
assay
compat
ht
identifi
inhibitor
lasv
lcmv
mammarenaviru
vrnp
activ
mammarenavirus
caus
chronic
infect
rodent
worldwid
distribut
human
infect
occur
mucos
exposur
aerosol
direct
contact
abrad
skin
infecti
materi
buchmeier
et
al
sever
mammarenavirus
caus
sever
diseas
human
pose
import
public
health
problem
endem
region
bray
geisbert
jahrl
thu
lassa
viru
lasv
mammarenaviru
highli
preval
west
africa
estim
infect
sever
hundr
thousand
individu
annual
result
high
number
lassa
fever
lf
case
diseas
associ
high
morbid
signific
lethal
patient
develop
sever
symptom
gunther
lenz
richmond
baglol
increas
travel
result
import
case
lf
nonendem
metropolitan
area
across
world
includ
us
freedman
woodal
isaacson
addit
mount
evid
indic
worldwidedistribut
mammarenaviru
lymphocyt
choriomening
viru
lcmv
neglect
human
pathogen
clinic
relev
bonthiu
bonthiu
bonthiu
also
pose
threat
immun
compromis
individu
macneil
et
al
palacio
et
al
food
drug
administr
fda
licens
mammarenaviru
vaccin
current
antimammarenaviru
therapi
limit
offlabel
use
ribavirin
partial
effect
caus
signific
side
effect
hadi
et
al
broadspectrum
inhibitor
favipiravir
gowen
et
al
mendenhal
et
al
safronetz
et
al
mammarenaviru
glycoprotein
gpc
mediat
fusion
inhibitor
cashman
et
al
shown
promis
result
anim
model
arenavir
hemorrhag
fever
hf
diseas
nevertheless
develop
addit
antimammarenaviru
drug
facilit
implement
combin
therapi
lasv
human
pathogen
mammarenavirus
approach
known
counteract
emerg
drug
resist
variant
often
observ
mono
therapi
strategi
domingo
likewis
identif
novel
inhibitor
mammarenaviru
multipl
serv
tool
compound
gener
new
knowledg
viru
biolog
uncov
previous
unexplor
pathway
specif
host
cell
factor
contribut
differ
step
viru
life
cycl
mammarenavirus
envelop
virus
biseg
neg
strand
ns
rna
genom
buchmeier
et
al
genom
segment
larg
l
small
use
ambisens
code
strategi
direct
synthesi
two
protein
opposit
orient
separ
noncod
intergen
region
igr
rna
encod
viral
http
receiv
septemb
receiv
revis
form
novemb
accept
novemb
nucleoprotein
np
viral
glycoprotein
precursor
gpc
whose
process
cellular
signal
peptidas
site
proteas
gener
acid
stabl
signal
peptid
ssp
matur
virion
surfac
glycoprotein
togeth
ssp
form
gp
complex
mediat
cell
entri
via
receptormedi
endocytosi
l
rna
encod
viral
rna
depend
rna
polymeras
l
polymeras
matrix
z
protein
advanc
mammarenaviru
molecular
genet
open
new
approach
develop
screen
strategi
identifi
inhibitor
mammarenaviru
multipl
emonet
et
al
miranda
et
al
welch
et
al
howev
use
approach
live
lasv
complic
requir
biosafeti
level
contain
viral
transact
factor
np
l
cisact
regulatori
sequenc
requir
format
function
viru
ribonucleoprotein
vrnp
complex
respons
direct
viral
genom
replic
gene
transcript
mammarenaviru
genom
defin
emonet
et
al
sarut
ross
use
knowledg
engin
cell
line
constitut
express
synthet
function
vrnp
lcmv
lcmvvrnp
lasv
lasvvrnp
encod
report
gene
lcmvvrnp
gaussia
luciferas
gluc
green
fluoresc
protein
gfp
lasvvrnp
gluc
zsgreen
zsg
whose
express
level
serv
accur
surrog
vrnp
activ
use
cellbas
infectiousfre
platform
develop
quantit
highthroughput
screen
ht
fulli
autom
robot
screen
system
ingles
et
al
kalypsi
use
multiplex
vrnacytotox
assay
identifi
inhibitor
lcmv
lasv
vrnp
activ
screen
lcmvvrnp
lasvvrnp
cell
line
four
librari
repres
total
uniqu
small
molecul
compound
confirm
compound
ec
gluc
assay
greater
select
gluc
cytotox
assay
either
cell
line
compound
includ
sever
known
ionophor
antibiot
inhibitor
mitochondri
electron
transport
chain
metc
complex
iii
select
confirm
hit
examin
effect
multipl
live
lcmv
cultur
cell
test
compound
exhibit
antilcmv
activ
context
bona
fide
lcmv
infect
consist
identif
screen
inhibitor
lcmv
lasv
vrnp
activ
test
compound
specif
inhibit
activ
lcmv
minigenom
mg
cellbas
transfect
assay
metc
complex
iii
inhibitor
antimycin
mubritinib
respect
exhibit
highest
antilcmv
activ
low
nm
half
maxim
effect
concentr
ec
high
select
index
si
si
cc
ec
valu
result
support
use
lcmvvrnp
lasvvrnp
cell
line
reliabl
platform
ht
identifi
inhibitor
activ
vrnp
respons
direct
biosynthet
process
replic
gene
transcript
viral
genom
benefit
infectiousfre
natur
platform
overcom
need
contain
requir
handl
live
lasv
pierc
gaussia
luciferas
gluc
glow
assay
kit
alamarblu
cell
viabil
reagent
purchas
thermofish
waltham
cell
cultur
media
select
purchas
thermofish
vero
atcc
atcc
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
mm
lglutamin
mgml
streptomycin
uml
penicillin
cell
stabli
express
monomer
red
fluoresc
protein
mrfp
blasticidin
bl
resist
gene
bsr
gentarget
inc
maintain
medium
cell
addit
bl
lcmvvrnp
cell
maintain
dmem
fb
puromycin
mgml
streptomycin
uml
penicillin
lasvvrnp
cell
maintain
dmem
fb
zeocin
bl
mgml
streptomycin
u
ml
penicillin
recombin
r
lcmv
express
gfp
refer
rlcmvgfp
miranda
et
al
zsgreen
zsg
refer
rlcmvzsg
singl
cycl
infecti
rlcmv
express
zsg
refer
describ
transfect
cell
well
plate
format
cellswel
pcagg
express
plasmid
lcmv
np
contain
ctermin
ha
epitop
tag
viral
l
polymeras
togeth
plasmid
use
lipofectamin
dna
plasmid
purgfp
direct
intracellular
synthesi
mediat
human
rna
polymeras
promot
hpoli
lcmvlike
rna
aka
minigenomemg
small
vrna
segment
antigenom
polar
express
gluc
instead
viral
glycoprotein
gpc
open
read
frame
orf
gene
resist
puromycin
fuse
nterminu
green
fluoresc
protein
purgfp
instead
viral
np
orf
overnight
transfect
cell
trypsin
resuspend
fb
dmem
serial
dilut
cm
cultur
plate
h
media
chang
fb
dmem
contain
puromycin
select
cell
express
purgfp
media
chang
everi
day
remov
dead
cell
puromycin
resist
coloni
collect
trypsin
use
clone
ring
directli
transfer
individu
well
well
plate
format
cell
expans
cell
well
plate
select
presenc
puromycin
amplifi
individu
clone
resist
puromycin
select
level
gfp
gluc
express
determin
viral
replic
transcript
activ
select
clone
confirm
express
report
gene
lcmv
l
np
treatment
ribavirin
nucleosid
analog
known
inhibit
arenaviru
viral
replic
transcript
clone
exhibit
optim
level
purgfp
gluc
express
show
dosedepend
inhibit
ribavirin
amplifi
aliquot
frozen
seed
cell
gentarget
inc
well
plate
precoat
polyllysin
cellswel
cultur
h
co
dmem
contain
fb
transfect
cell
pcagg
express
plasmid
lasv
np
l
togeth
plasmid
use
lipofectamin
dna
plasmid
direct
intracellular
synthesi
mediat
human
rna
polymeras
hpoli
lasvlik
rna
aka
minigenomemg
segment
genom
polar
gpc
orf
replac
gluc
report
gene
np
orf
sh
ble
gene
confer
resist
zeocin
zeor
fuse
nterminu
zsg
report
gene
separ
peptid
sequenc
deriv
porcin
teschoviru
szymczakworkman
et
al
h
transfect
cell
wash
dmem
fed
dmem
contain
fb
h
subject
transfect
cell
zeo
select
select
cell
express
zeorzsg
select
done
six
day
chang
medium
day
remov
dead
cell
coloni
cell
resist
zeo
collect
trypsin
use
clone
disc
individu
coloni
transfer
well
plate
b
cubitt
et
al
antivir
research
select
zeo
select
cell
clone
screen
zsg
express
respons
ribavirin
valid
inhibitor
mammarenaviru
vrnp
activ
clone
exhibit
optim
ribavirin
dosedepend
inhibit
zsg
express
select
analyz
select
clone
fluorescenceactiv
cell
sort
fac
remov
outlier
highest
lowest
zsg
express
cell
clonal
popul
major
zsg
express
cell
sort
cell
clone
amplifi
continu
zeo
select
frozen
aliquot
made
low
passag
express
np
l
mrna
assess
rtpcr
total
rna
isol
parent
lcmvvrnp
cell
use
tri
reagent
molecular
research
center
accord
manufactur
instruct
total
rna
revers
transcrib
cdna
use
iv
firststrand
synthesi
system
thermo
fisher
scientif
waltham
use
random
hexam
prime
pcr
done
use
specif
primer
lcmv
np
forward
revers
agtgtcacaacatttgggcc
lcmv
l
forward
gggatggatgaaatcatctc
revers
ttagtgtcctctat
express
np
detect
indirect
immunofluoresc
iif
western
blot
wb
assay
iif
cell
fix
paraformaldehyd
pfa
pb
permeabil
block
triton
pb
contain
bovin
serum
albumin
bsa
block
cell
incub
antiha
monoclon
antibodi
sigma
probe
fitcconjug
rabbit
antimous
secondari
antibodi
dako
wb
lcmvvrnp
parent
cell
cellswel
plate
format
collect
lyse
lysi
buffer
mm
trishcl
ph
mm
edta
mm
nacl
complet
cocktail
proteas
inhibitor
roch
aliquot
total
cell
lysat
separ
sdspage
transfer
onto
nitrocellulos
membran
biorad
membran
incub
antiha
monoclon
antibodi
sigma
probe
secondari
hrpconjug
antimous
antibodi
ge
healthcar
lcmv
np
express
detect
use
chemiluminesc
kit
denvil
scientif
cellular
gapdh
detect
use
polyclon
antibodi
gapdh
abcam
express
np
l
mrna
assess
rtpcr
total
rna
isol
parent
lasvvrnp
cell
use
tri
reagent
molecular
research
center
accord
manufactur
instruct
total
rna
revers
transcrib
cdna
use
iv
firststrand
synthesi
system
thermo
fisher
scientif
waltham
use
random
hexam
prime
semiquantit
revers
transcriptasepolymeras
chain
reaction
rtpcr
done
use
specif
primer
lasv
np
forward
revers
lasv
l
forward
revers
gapdh
forward
revers
express
np
assess
iif
parent
lasvvrnp
cell
seed
onto
polyllysin
coat
glass
coverslip
allow
grow
h
prior
fixat
pfa
cell
permeabil
block
triton
pb
contain
bsa
block
cell
incub
mous
monoclon
lasvnp
follow
secondari
goat
antimous
antibodi
conjug
alexa
fluor
thermofish
allow
lasvnp
visual
use
far
red
wavelength
nuclei
visual
dapi
stain
lcmv
lasv
vrnp
cell
revers
transfect
pmol
sirna
lcmv
lasv
l
polymeras
respect
use
lipofectamin
rnaimax
nm
final
sirna
concentr
cell
examin
gfp
lcmvvrnp
zsg
lasvvrnp
express
h
treatment
compar
nontransfect
control
cell
antilcmv
l
antilasvl
sirna
design
use
rnai
design
softwar
thermofish
scientif
select
sirna
molecul
synthes
invitrogen
lasvvrnp
lcmvvrnp
cell
seed
white
solid
bottom
tissu
cultur
treat
microtit
plate
greiner
bioon
cellswel
growth
media
plate
incub
h
co
follow
addit
nl
compound
dmso
well
via
pintool
kalypsi
cell
incub
compound
h
co
alamarblu
viabil
reagent
dispens
well
use
multidro
combi
thermofish
plate
incub
h
co
fluoresc
signal
read
excit
nm
emiss
nm
gluc
report
express
assay
dispens
gluc
substrat
lysi
buffer
follow
min
incub
room
temperatur
luminesc
signal
read
quantit
ht
qht
done
fulli
autom
robot
screen
system
ingles
et
al
kalypsi
lasvvrnp
lcmvvrnp
cell
line
screen
four
librari
use
multiplex
vrnacytotox
assay
buchmeier
et
al
librari
pharmacolog
activ
compound
lopac
collect
small
molecul
character
biolog
activ
purchas
sigmaaldrich
st
loui
mo
usa
bray
nation
center
advanc
translat
scienc
ncat
pharmaceut
collect
npc
approv
investig
drug
collect
gener
hous
huang
et
al
time
screen
npc
librari
consist
small
molecul
compound
drug
approv
human
veterinari
use
unit
state
food
drug
administr
fda
drug
approv
europ
canada
japan
remain
compound
enter
clinic
trial
research
compound
commonli
use
biomed
research
geisbert
jahrl
mechan
interrog
plate
mipe
librari
approv
investig
drug
gunther
lenz
npact
librari
natur
product
compound
lopac
npc
npact
librari
screen
concentr
point
dilut
rang
nm
compound
mipe
librari
screen
concentr
point
dilut
rang
nm
select
valu
calcul
cc
alamarblu
assay
divid
ec
gluc
assay
compound
cytotox
observ
highest
concentr
test
valu
use
cc
valu
select
calcul
cell
viabil
assess
use
celltit
aqueou
one
solut
reagent
promega
cell
seed
clear
bottom
plate
x
cellswel
h
later
treat
serial
dilut
compound
four
replic
compound
concentr
h
drug
treatment
celltit
aqueou
one
solut
reagent
promega
ad
well
plate
incub
min
co
absorb
measur
nm
use
enzymelink
immunosorb
assay
elisa
reader
spectra
max
plu
molecular
devic
sunnyval
ca
valu
normal
vehicl
control
group
dmso
adjust
cytotox
concentr
cc
determin
use
graphpad
prism
determin
compound
half
maxim
effect
concentr
ec
cell
plate
clear
bottom
black
plate
x
cellswel
incub
h
co
cell
infect
multipl
infect
moi
treat
serial
dilut
compound
four
replic
compound
concentr
h
postinfect
pi
cell
fix
paraformaldehyd
gfp
express
level
determin
fluoresc
use
fluoresc
plate
reader
synergi
hybrid
multimod
micropl
reader
biotek
winooski
vt
mean
valu
normal
infect
vehicl
dmso
treat
control
group
adjust
gfp
express
level
also
normal
total
cell
protein
lysat
pierc
bca
protein
assay
kit
thermo
scientif
ec
valu
determin
use
graphpad
prism
graphpad
softwar
san
diego
ca
primari
screen
data
analyz
use
custom
softwar
develop
intern
wang
et
al
data
present
mean
standard
error
mean
sem
cell
x
cellswel
well
plate
format
triplic
infect
moi
min
adsorpt
viru
inoculum
remov
cell
wash
twice
dmem
fb
fresh
complet
medium
contain
indic
compound
concentr
ad
indic
hour
pi
tissu
cultur
supernat
tc
collect
viral
titer
determin
focu
form
assay
battegay
briefli
serial
dilut
triplic
viru
sampl
use
infect
vero
cell
monolay
well
plate
cellswel
h
pi
cell
fix
paraformaldehyd
pfa
pb
foci
rlcmvgfpinfect
cell
determin
directli
epifluoresc
valid
immunofluoresc
use
rat
monoclon
antibodi
np
conjug
alexa
fluor
lcmv
mg
assay
perform
previous
describ
iwasaki
et
al
iwasaki
et
al
cell
cultur
polyllysin
coat
well
plate
x
cellswel
day
transfect
cell
transfect
set
plasmid
contain
polymeras
pcagg
pcagg
np
pcagg
l
use
lipofectamin
dna
thermo
fisher
scientif
h
transfect
mixtur
replac
fresh
medium
contain
test
compound
follow
h
incub
co
h
posttransfect
whole
cell
lysat
harvest
determin
level
gfp
briefli
whole
cell
lysat
prepar
ml
lysi
buffer
mm
tri
ph
mm
edta
mm
nacl
gfp
level
measur
equival
amount
clarifi
lysat
use
synergi
reader
cell
cultur
polyllysin
coat
well
plate
x
cellswel
day
transfect
cell
transfect
pcagg
pcagg
lasv
np
pcagg
lasv
l
use
lipofectamin
dna
thermo
fisher
scientif
h
transfect
mixtur
replac
fresh
medium
contain
test
compound
follow
h
incub
co
h
posttransfect
whole
cell
lysat
harvest
determin
level
zsgreen
briefli
whole
cell
lysat
prepar
ml
lysi
buffer
mm
tri
ph
mm
edta
mm
nacl
zsgreen
level
measur
use
synergi
reader
use
equival
amount
clarifi
lysat
normal
total
cell
protein
lysat
pierc
bca
protein
assay
kit
thermo
scientif
mean
valu
normal
vehicl
dmso
treat
control
group
v
adjust
aim
engin
infectiousfre
cell
platform
accur
recreat
rna
replic
gene
transcript
biosynthet
process
lasv
infect
cell
enabl
screen
protocol
identifi
inhibitor
lasv
vrnp
activ
without
requir
contain
first
explor
feasibl
approach
use
lcmv
system
would
allow
us
compar
result
obtain
virusfre
cell
platform
live
viru
infect
construct
plasmid
direct
intracellular
synthesi
mediat
human
rna
polymeras
promot
lcmvlike
vrna
aka
minigenomemg
segment
antigenom
polar
crna
np
orf
replac
pur
resist
gene
fuse
nterminu
gfp
purgfp
gpc
orf
gluc
report
gene
fig
transfect
cell
plasmid
togeth
polymeras
ii
express
pcagg
plasmid
encod
lcmv
np
l
minim
transact
viral
factor
requir
lcmv
genom
replic
gene
express
hass
et
al
lee
et
al
fig
h
posttransfect
plate
cell
dish
low
densiti
subject
select
presenc
pur
select
cell
clone
express
function
lcmv
vrnp
determin
high
level
gfp
gfp
cell
fluoresc
unit
parent
control
cell
gluc
induct
parent
control
cell
fig
use
similar
approach
gener
construct
gluc
substitut
gpc
orf
np
orf
replac
fig
select
purgfp
use
lcmv
base
evid
support
superior
perform
zeocin
select
agent
develop
human
cell
line
lanza
et
al
stronger
mean
intens
fluoresc
zsg
compar
gfp
direct
intracellular
synthesi
lasv
mg
rna
speci
genom
polar
antisens
polar
respect
promot
prevent
possibl
could
direct
synthesi
rna
speci
despit
lack
cap
polyadenyl
could
result
low
level
express
introduc
confound
factor
cell
line
select
engin
cell
line
express
function
lasv
vrnp
use
commerci
avail
gentarget
inc
cell
stabli
express
monomer
red
fluoresc
protein
mrfp
blasticidin
resist
gene
bsr
approach
facilit
rapid
identif
compound
may
significantli
interfer
poliimedi
express
therebi
could
affect
express
viral
np
lp
consequ
effect
vrnp
activ
zsg
mrfp
differ
excit
emiss
spectra
shaner
et
al
therefor
express
level
sampl
determin
without
mutual
interfer
transfect
cell
togeth
polii
pcagg
express
vector
lasv
np
l
use
zeocin
treatment
select
cell
express
function
lasv
vrnp
determin
high
level
zsg
zsg
cell
fu
nonexpress
vrnp
control
cell
gluc
induct
parent
control
cell
confirm
express
np
l
mrna
protein
lcmv
lasv
lcmvvrnp
lasvvrnp
respect
cell
line
fig
detect
lcmv
np
l
mrna
done
rtpcr
fig
express
lcmv
np
assess
iif
fig
wb
fig
use
antibodi
ctermin
ha
epitop
tag
present
lcmv
np
detect
lasv
np
l
mrna
done
rtpcr
fig
express
lasv
np
assess
iif
fig
use
mous
monoclon
antibodi
lasv
np
character
cell
clone
express
lcmv
lasv
function
vrnp
identifi
optim
properti
use
develop
assay
ht
identifi
inhibitor
viral
rna
genom
replic
gene
transcript
use
follow
criteria
l
polymeras
depend
vrnpdirect
report
gene
express
confirm
reduc
express
level
gfp
zsg
caus
treatment
sirna
specif
target
lcmv
lasv
l
polymeras
respect
fig
sensit
inhibitori
effect
ribavirin
valid
inhibitor
lcmv
lasv
rna
replic
transcript
fig
well
favipiravir
fig
two
describ
inhibitor
activ
lcmv
lasv
vrnp
mendenhal
et
al
ortizriano
et
al
predict
found
multipl
rlcmv
express
gfp
rlcmvgfp
gfp
express
direct
lcmvvrnp
inhibit
inhibitor
mediat
process
arenaviru
gpc
urata
et
al
fig
also
confirm
mrfp
express
level
lasvvrnp
cell
significantli
affect
ribavirin
favipiravir
growth
properti
lasvvrnp
lcmv
vrnp
cell
line
similar
exhibit
respect
parent
cell
line
sustain
high
express
level
report
gene
passag
cultur
cell
also
includ
criteria
cell
clone
select
viabil
upon
freezethaw
step
reproduc
assay
perform
batchtobatch
assess
feasibl
use
vrnpcell
line
platform
implement
ht
identifi
inhibitor
lcmv
lasv
vrnp
genom
replic
gene
transcript
evalu
perform
lcmvvrnp
lasvvrnp
cell
line
plate
format
assay
seed
lcmvvrnp
lasvvrnp
cell
plate
black
optic
clear
bottom
greiner
bio
differ
densiti
differ
postseed
time
treat
cell
ribavirin
known
inhibit
lcmv
ortizriano
et
al
lasv
multipl
dosedepend
manner
differ
time
h
posttreat
ribavirin
determin
express
level
gluc
tissu
cultur
supernat
gfp
lcmvvrnp
zsg
lasvvrnp
cell
use
dapi
stain
estim
cell
biomass
avoid
differ
cell
number
confound
factor
valu
vrnp
activ
observ
cubitt
et
al
antivir
research
expect
dosedepend
inhibitori
activ
ribavirin
lcmv
lasv
vrnpdirect
express
gluc
gfp
lcmv
zsg
lasv
obtain
optim
result
lcmvvrnp
lasvvrnp
cell
line
replicatescondit
use
follow
condit
seed
cellswel
compound
ribavirin
addit
h
cell
seed
assay
read
h
start
ribavirin
treatment
assay
signal
background
ratio
b
gluc
gfp
lcmv
zsg
lasv
readout
determin
compar
signal
obtain
vrnpexpress
line
control
cell
lack
correspond
vrnp
observ
inhibit
lcmv
lasv
vrnp
activ
ribavirin
select
ribavirin
concentr
gener
minim
signal
assay
evalu
assay
signal
dynam
rang
data
variat
associ
sampl
measur
determin
factor
valu
gluc
zsgbase
readout
lasv
vrnp
activ
ribavirintr
lasvvrnp
cell
use
maxim
max
minim
min
report
signal
valu
obtain
ribavirin
respect
subtract
background
signal
fig
optim
assay
condit
consist
observ
z
gluc
zsgbase
readout
presenc
ribavirin
z
factor
valu
compat
assay
adapt
ht
iversen
et
al
zhang
et
al
highest
concentr
test
ribavirin
minim
effect
cell
viabil
prevent
us
assess
respons
cellbas
assay
compound
induc
toxic
address
issu
examin
dosedepend
effect
dmso
cell
viabil
vrnpdirect
report
gene
express
determin
dmso
toler
assay
also
critic
import
primari
screen
done
singl
dose
compound
prepar
dmso
would
requir
assay
compat
compound
contribut
dmso
final
volum
found
concentr
dmso
signific
effect
viabil
lcmvvrnp
lasvvrnp
cell
line
wherea
subsequ
increas
dmso
result
dosedepend
cell
toxic
determin
celltiterfluor
cell
viabil
assay
correl
reduc
level
vrnp
direct
express
gfp
lcmvvrnp
zsg
lasvvrnp
gluc
lcmvvrnp
lasvvrnp
activ
lcmv
lasv
vrnp
assay
determin
express
level
gluc
report
gene
optim
biolog
respons
requir
h
incub
period
therefor
compound
cytotox
effect
could
present
fals
posit
identifi
elimin
cytotox
compound
primari
screen
multiplex
assay
develop
use
alamarblu
viabil
reagent
readout
cytotox
lyse
cell
assay
gluc
activ
multiplex
assay
test
format
found
robust
perform
lasvvrnp
lcmvvrnp
cell
line
fig
total
uniqu
small
molecul
compound
screen
qht
format
lasvvrnp
lcmvvrnp
cell
line
use
multiplex
vrnp
assay
data
deposit
pubchem
aid
lasv
luciferas
data
aid
lasv
viabil
data
aid
lcmv
luciferas
data
aid
lcmv
viabil
data
total
uniqu
compound
show
greater
select
gluc
activ
versu
alamarblu
activ
either
lasv
lcmv
cell
line
cherri
pick
confirm
confirm
done
titrat
duplic
cell
line
use
multiplex
vrnp
assay
confirm
data
found
pubchem
aid
lasv
luciferas
data
aid
lasv
viabil
data
lcmv
luciferas
data
aid
lcmv
viabil
data
upon
confirm
compound
show
ec
luciferas
assay
greater
select
luciferas
alamarblu
assay
either
cell
line
tabl
three
compound
identifi
separ
librari
test
twice
compound
cherri
pick
mm
dmso
solut
test
follow
assay
confirm
identifi
hit
target
activ
vrnp
use
transient
transfect
base
lcmv
examin
effect
select
hit
viral
genom
replic
gene
express
direct
lcmv
lasv
mg
express
either
gfp
lcmv
mg
zsgreen
lasv
mg
np
locu
transfect
cell
lcmv
lasv
togeth
polii
pcagg
express
vector
rna
polymeras
l
np
transact
factor
lcmv
fig
lasv
fig
transfect
done
presenc
indic
compound
concentr
h
posttransfect
prepar
cell
lysat
measur
level
gfp
zsgreen
express
four
narasin
manassantin
antimycin
pimozid
three
narasin
manassantin
antimycin
test
hit
lcmv
fig
lasv
fig
respect
mg
system
observ
dosedepend
inhibitori
effect
mg
activ
select
hit
abil
inhibit
activ
lasv
lcmv
vrnp
examin
effect
multipl
live
lcmv
fig
treat
cell
serial
dilut
compound
start
h
prior
infect
moi
rlcmvgfp
maintain
compound
throughout
cours
infect
h
determin
gfp
express
level
also
examin
dosedepend
effect
select
hit
cell
viabil
use
celltit
aqueou
one
solut
reagent
level
gfp
express
normal
assign
valu
gfp
express
level
vehicl
control
vc
treat
dmso
infect
cell
valu
cell
viabil
normal
assign
valu
vctreat
cell
use
normal
valu
determin
compound
ec
cc
valu
correspond
select
index
si
si
cc
ec
valu
fig
among
hit
evalu
four
exhibit
si
fig
observ
correl
ec
valu
degre
hit
interf
propag
lcmv
cultur
cell
fig
product
lcmv
infecti
progeni
fig
h
pi
develop
cellbas
platform
allow
screen
compound
affect
viral
rna
genom
replic
andor
gene
transcript
biosynthet
process
direct
vrnp
lcmv
lasv
platform
base
gener
human
cell
line
stabli
express
lcmv
lasv
transact
factor
np
l
requir
format
function
vrnp
togeth
viruslik
rna
mg
encod
report
gene
whose
express
level
serv
accur
surrog
vrnp
activ
gener
lcmvvrnp
lasvvrnp
cell
line
facilit
mg
express
fusion
gene
drug
resist
gene
report
gene
dynam
rang
reproduc
vrnpdirect
report
gene
express
respons
known
inhibitor
lcmv
lasv
rna
synthesi
valid
use
lcmvvrnp
lasvvrnp
cell
line
implement
ht
approach
identifi
inhibitor
lcmv
lasv
vrnp
activ
central
goal
gener
infectiousfre
cell
system
identifi
compound
modul
lasv
rna
synthesi
mediat
intracellularli
reconstitut
function
vrnp
without
need
contain
compound
would
includ
candid
antivir
drug
tool
compound
investig
mechan
regul
vrnpdirect
lasv
rna
synthesi
examin
feasibl
approach
first
gener
lcmvvrnp
cell
line
confirm
faith
recreat
biosynthet
featur
vrnp
observ
context
lcmvinfect
cell
rna
synthesi
viral
rna
depend
rna
polymeras
modul
host
cell
factor
ahlquist
et
al
bortz
et
al
accordingli
activ
mammarenaviru
vrnp
like
involv
viral
proteinprotein
proteinrna
interact
well
contribut
host
cell
factor
compound
target
function
viral
protein
interact
requir
vrnp
activ
expect
offer
specif
inhibitorescap
mutant
isol
virtual
viru
specif
inhibitor
develop
pose
gener
problem
antivir
therapi
domingo
combin
therapi
proven
effect
reduc
delay
select
viral
escap
mutant
entir
solv
problem
domingo
contrast
intrahost
viru
evolut
unlik
result
viral
variant
abl
escap
inhibitor
disrupt
cellular
function
requir
vrnp
activ
moreov
vrnp
relat
virus
like
lcmv
lasv
like
reli
host
cell
factor
activ
thu
compound
target
host
cell
factor
provid
opportun
develop
broadspectrum
antivir
therapeut
target
host
cell
factor
pose
concern
drugassoci
toxic
howev
note
treatment
acut
arenavir
hf
diseas
would
rel
short
durat
clinic
benefit
may
easili
surpass
potenti
short
term
durat
side
effect
also
note
compound
inhibit
lasv
lcmv
via
mechan
action
use
studi
use
wellestablish
mous
model
lcmv
infect
gain
valuabl
inform
design
effect
studi
anim
model
lasv
infect
minim
cost
complex
logist
use
contain
requir
handl
live
form
lasv
antimycin
metc
complex
iii
inhibitor
raveh
et
al
human
epiderm
factor
receptor
inhibitor
mubritinib
inhibit
lcmv
lasv
vrnp
effect
select
hit
product
infecti
lcmv
progeni
cell
infect
moi
rlcmvgfp
treat
indic
compound
h
pi
tissu
cultur
supernat
tc
collect
titer
infecti
viru
determin
base
foci
rlcmv
gfpinfect
cell
identifi
epifluoresc
valid
immunofluoresc
use
rat
monoclon
antibodi
np
conjug
alexa
fluor
tc
titer
normal
assign
valu
tc
titer
vctreat
dmso
cell
result
correspond
averag
two
biolog
replic
sd
shown
experiment
endpoint
h
pi
cell
viabil
determin
celltit
aqueou
one
solut
reagent
promega
test
compound
except
papaverin
treatment
result
cell
viabil
differ
si
compound
high
si
valu
lcmv
vrnp
lower
si
valu
lasv
vrnp
due
activ
alamarblu
assay
tabl
observ
trend
mani
compound
exhibit
signific
higher
cytotox
lasvvrnp
cell
lcmvvrnp
cell
may
critic
contribut
consist
lower
si
valu
lasvvrnp
cell
lcmvvrnp
lasvvrnp
line
gener
use
gentarget
inc
respect
parent
cell
addit
despit
phylogenet
proxim
lcmv
lasv
exhibit
signific
degre
genet
diverg
multipl
amino
acid
differ
np
l
polymeras
protein
plausibl
differ
parent
cell
line
combin
differ
amino
acid
composit
compon
vrnp
contribut
lcmvvrnp
lasvvrnp
cell
line
exhibit
differ
suscept
specif
compound
impact
si
valu
obtain
compound
lcmvvrnp
lasvvrnp
cell
line
mubritinib
recent
identifi
novel
metc
complex
inhibitor
baccelli
ig
et
al
may
contribut
antilcmv
activ
moreov
rotenon
anoth
valid
metc
complex
inhibitor
majand
et
al
exhibit
also
potent
ec
si
antilcmv
activ
impair
metc
function
suppress
autophagi
shown
caus
reduc
product
infecti
progeni
mammarenaviru
lasv
baillet
et
al
de
novo
pyrimidin
biosynthesi
also
link
metc
activ
via
dihydroorot
dehydrogenas
dhodh
loffler
et
al
dhodh
inhibitor
shown
potent
broadspectrum
antivir
hoffmann
et
al
clinic
implement
inhibitor
metc
function
antivir
agent
rais
object
relat
expect
potenti
toxic
howev
metc
complex
inhibitor
biguanid
metformin
wide
prescrib
antihyperglycaem
type
ii
diabet
good
safeti
profil
bridg
et
al
na
k
ionophor
antibiot
narasin
valinomycin
respect
exhibit
also
strong
inhibitori
effect
lcmv
lasv
vrnp
activ
narasin
shown
exert
antivir
activ
dengu
viru
low
et
al
wherea
valinomycin
identifi
potent
hit
cellbas
screen
identifi
effect
antivir
sever
acut
respiratori
syndrom
coronaviru
sarscov
wu
et
al
develop
stabl
human
cell
line
constitut
express
function
vrnp
lcmv
lasv
use
cell
line
identif
inhibitor
lcmv
lasv
rna
genom
replic
gene
transcript
use
ht
approach
infectivityfre
featur
lasv
vrnpexpress
cell
line
overcom
need
facil
current
requir
handl
infecti
lasv
potenti
acceler
develop
antivir
lasv
use
vrnpexpress
cell
line
drug
repurpos
screen
identifi
compound
inhibit
lcmv
lasv
vrnp
activ
importantli
subset
test
compound
inhibit
multipl
live
lcmv
cultur
cell
exist
knowledg
target
antivir
compound
would
suggest
metc
potenti
target
therapeut
mammarenavirus
well
merit
explor
ionophorebas
compound
potenti
antivir
lasv
futur
studi
beyond
scope
present
paper
examin
whether
newli
identifi
compound
abil
inhibit
lcmv
lasv
vrnp
activ
also
activ
hfcaus
new
world
arenaviru
junin
viru
well
antivir
activ
compound
anim
model
mammarenaviru
infect
